vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
Company profile
Ticker
VNDA
Exchange
Website
CEO
Mihael Polymeropoulos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Vanda Pharmaceuticals Limited • Vanda Pharmaceuticals GmbH • Vanda Pharmaceuticals Germany GmbH • Vanda Pharmaceuticals Netherlands B.V. ...
IRS number
30491827
VNDA stock data
Latest filings (excl ownership)
8-K
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
7 Mar 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
8-K/A
Special Purpose Abbreviated Financial Statements
16 Feb 24
10-K
2023 FY
Annual report
8 Feb 24
8-K
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7 Feb 24
8-K
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
5 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Dec 23
8-K
Entry into a Material Definitive Agreement
7 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
8 Nov 23
Transcripts
VNDA
Earnings call transcript
2023 Q4
7 Feb 24
VNDA
Earnings call transcript
2023 Q3
8 Nov 23
VNDA
Earnings call transcript
2023 Q2
27 Jul 23
VNDA
Earnings call transcript
2023 Q1
3 May 23
VNDA
Earnings call transcript
2022 Q4
8 Feb 23
VNDA
Earnings call transcript
2022 Q3
3 Nov 22
VNDA
Earnings call transcript
2022 Q2
3 Aug 22
VNDA
Earnings call transcript
2022 Q1
5 May 22
VNDA
Earnings call transcript
2021 Q4
24 Feb 22
VNDA
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
4
Timothy Williams
6 Mar 24
4
Joakim Wijkstrom
6 Mar 24
4
Mihael Hristos Polymeropoulos
6 Mar 24
4
Kevin Patrick Moran
6 Mar 24
4
Gunther Birznieks
6 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 183.66 mm | 183.66 mm | 183.66 mm | 183.66 mm | 183.66 mm | 183.66 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.00 mm | (no burn) | 683.33 k | (no burn) |
Cash used (since last report) | n/a | n/a | 11.88 mm | n/a | 4.06 mm | n/a |
Cash remaining | n/a | n/a | 171.77 mm | n/a | 179.59 mm | n/a |
Runway (months of cash) | n/a | n/a | 86.0 | n/a | 262.8 | n/a |
Institutional ownership, Q3 2023
90.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 179 |
Opened positions | 29 |
Closed positions | 36 |
Increased positions | 64 |
Reduced positions | 65 |
13F shares | Current |
---|---|
Total value | 224.19 bn |
Total shares | 52.20 mm |
Total puts | 14.20 k |
Total calls | 4.50 k |
Total put/call ratio | 3.2 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 6.76 mm | $29.20 bn |
Vanguard | 3.48 mm | $15.01 bn |
Renaissance Technologies | 3.27 mm | $14.13 bn |
Dimensional Fund Advisors | 2.16 mm | $9.35 bn |
Millennium Management | 2.02 mm | $8.71 bn |
D. E. Shaw & Co. | 1.95 mm | $8.41 bn |
Acadian Asset Management | 1.75 mm | $7.57 bn |
Pictet Asset Management Holding | 1.74 mm | $7.51 bn |
GS Goldman Sachs | 1.67 mm | $7.23 bn |
MS Morgan Stanley | 1.59 mm | $6.87 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Mar 24 | Timothy Williams | Common Stock | Sell | Dispose S | No | No | 4.1825 | 8,941 | 37.40 k | 196,825 |
5 Mar 24 | Joakim Wijkstrom | Common Stock | Sell | Dispose S | No | No | 4.2074 | 9,229 | 38.83 k | 129,789 |
5 Mar 24 | Mihael Hristos Polymeropoulos | Common Stock | Sell | Dispose S | No | No | 4.1285 | 24,288 | 100.27 k | 1,871,730 |
5 Mar 24 | Kevin Patrick Moran | Common Stock | Sell | Dispose S | No | No | 4.2025 | 8,902 | 37.41 k | 231,014 |
5 Mar 24 | Gunther Birznieks | Common Stock | Sell | Dispose S | No | No | 4.1322 | 8,684 | 35.88 k | 313,569 |
4 Mar 24 | Timothy Williams | Common Stock | Sell | Dispose S | No | No | 4.4086 | 8,147 | 35.92 k | 205,766 |
4 Mar 24 | Joakim Wijkstrom | Common Stock | Sell | Dispose S | No | No | 4.4133 | 7,498 | 33.09 k | 139,018 |
4 Mar 24 | Mihael Hristos Polymeropoulos | Common Stock | Sell | Dispose S | No | No | 4.2438 | 30,884 | 131.07 k | 1,896,018 |
4 Mar 24 | Kevin Patrick Moran | Common Stock | Sell | Dispose S | No | No | 4.4812 | 5,798 | 25.98 k | 239,916 |
4 Mar 24 | Gunther Birznieks | Common Stock | Sell | Dispose S | No | No | 4.2964 | 8,727 | 37.49 k | 322,253 |
News
Vanda Pharma: Q4 Earnings Insights
7 Feb 24
Vanda Pharma Q4 2023 GAAP EPS $(0.04) Beats $(0.09) Estimate, Sales $45.27M Beat $37.00M Estimate
7 Feb 24
Earnings Scheduled For February 7, 2024
7 Feb 24
Earnings Preview For Vanda Pharma
6 Feb 24
Vanda Pharmaceuticals Announces FDA Update For Supplemental NDA For HETLIOZ
5 Feb 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
27 Mar 24
Thinking about buying stock in Intellicheck, Vanda Pharmaceuticals, Dave Inc, Invivyd, or Dream Finders Homes?
25 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
23 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
19 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA
15 Mar 24